Presentation on theme: "Abetimus Sodium (LJP 394) a synthetic Toleragen molecule consisting of four double-stranded oligodeoxyribonucleotides attached to nonimmunogenic polyethylene."— Presentation transcript:
Abetimus Sodium (LJP 394) a synthetic Toleragen molecule consisting of four double-stranded oligodeoxyribonucleotides attached to nonimmunogenic polyethylene glycol an immunomodulating agent that induces tolerance in B cells directed against double-stranded DNA (dsDNA) – by cross-linking surface antibodies, which are thought to be responsible for lupus nephritis in SLE
Abetimus Sodium (LJP 394) In a study conducted by Alarcon-Segovia et al.(2003), treatment with LJP 394 in patients with high-affinity antibodies to its DNA epitope: – prolonged the time to renal flare – decreased the number of renal flares – required fewer HDCC treatments compared with placebo The drug also appeared to be well tolerated among the patients treated in the study. Alarcon-Segovia, D. et al.(2003). LJP 394 for the prevention of renal flare in patients with systemic lupus erethematosus. Arthritis & Rheumatism, 48(2) 442-454.
The Euro-Lupus Nephritis Trial The data from the ELNT indicate that in European SLE patients with proliferative lupus nephritis, a remission-inducing regimen of low-dose IV CYC (cumulative dose 3 gm) followed by AZA achieves clinical results comparable to those obtained with high-dose regimen. Low-dose intravenous cyclophosphamide could be used as an alternative to a high-dose regimen and was associated with half as many severe infections. Other advantages include no hospitalization and virtually no risk of premature gonadal failure. Houssiau et al. (2002).Immunosuppressive therapy in lupus nephritis: the euro-lupus nephritis tral, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis & Rheumatism, 46(8) 2121-2131.